Pubblicazioni

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

2022 - THE LANCET. HAEMATOLOGY

Dimopoulos, Meletios A; Richardson, Paul G; Bahlis, Nizar J; Grosicki, Sebastian; Cavo, Michele; BeksaÃ§, Meral; LegieÄ, Wojciech; Liberati, Anna M; Goldschmidt, Hartmut; Belch, Andrew; Magen, Hila; Larocca, Alessandra; Laubach, Jacob P; Petrucci, Maria T; Reece, Donna; White, Darrell; Mateos, MarÃa-Victoria; Å piÄka, Ivan; Lazaroiu, Mihaela; Berdeja, JesÃºs; Kaufman, Jonathan L; Jou, Ying-Ming; Ganetsky, Alex; Popa McKiver, Mihaela; Lonial, Sagar; Weisel, Katja; Martelli, Maurizio

The role of endogenous Antisecretory Factor (AF) in the treatment of MÃ©niÃ¨re's Disease: A two-year follow-up study. Preliminary results

2020 - AMERICAN JOURNAL OF OTOLARYNGOLOGY

Viola, P.; Pisani, D.; Scarpa, A.; Cassandro, C.; Laria, C.; Aragona, T.; Ciriolo, M.; Spadera, L.; Ralli, M.; Cavaliere, M.; Iengo, M.; Chiarella, G.

Twelve-month results of a single or multiple dexamethasone intravitreal implant for macular edema following uncomplicated phacoemulsification

2015 - BIOMED RESEARCH INTERNATIONAL

Abdolrahimzadeh, Solmaz; Fenicia, Vito; Maurizi Enrici, Maurizio; Plateroti, Pasquale; Cianfrone, Dora; Recupero, Santi Maria